Dermatology Subspecialties: Mohs Surgery, Pediatric, Cosmetic, and More

Dermatology encompasses a broad range of subspecialties, each defined by a distinct patient population, technical skill set, or disease category. Understanding how these subspecialties are structured helps patients, referring physicians, and policymakers navigate care pathways more precisely. The American Board of Dermatology (ABD) formally recognizes subspecialty certifications, and the scope of each area is further shaped by standards from federal agencies and professional societies. For broader context on how the field is governed, the regulatory context for dermatology outlines the legal and institutional frameworks that apply across practice settings.

Definition and Scope

Dermatology is formally divided into subspecialties recognized through fellowship training and, in some cases, separate board certification. The American Board of Dermatology currently administers subspecialty certification in 3 areas: Micrographic Dermatologic Surgery (Mohs surgery), Dermatopathology, and Pediatric Dermatology. Additional subspecialty areas — including cosmetic dermatology and immunodermatology — are practiced without separate ABD board certification but are defined by fellowship curricula set by organizations such as the American Society for Dermatologic Surgery (ASDS).

The distinction between subspecialties matters because scope of practice, procedural credentialing, and insurance reimbursement vary across them. For example, cosmetic procedures may be classified differently under CPT coding and payer contracts than oncologic procedures, a divide explored in detail on the cosmetic vs. medical dermatology page. The overview of the full specialty landscape is available at the dermatology home index.

Major recognized subspecialties include:

1. Mohs Micrographic Surgery — surgical excision of skin cancer with real-time margin analysis
2. Pediatric Dermatology — skin disease in patients from birth through adolescence
3. Dermatopathology — microscopic analysis of skin tissue, often dual-boarded with pathology
4. Cosmetic Dermatology — aesthetic procedures including injectables, lasers, and chemical peels
5. Immunodermatology — autoimmune and immunologically mediated skin diseases
6. Photomedicine — therapeutic and diagnostic use of light
7. Teledermatology — remote dermatologic consultation via digital imaging platforms

How It Works

Each subspecialty follows a defined training and credentialing pathway after core dermatology residency, which the Accreditation Council for Graduate Medical Education (ACGME) accredits. Core residency spans 3 years following a 1-year internship, totaling 4 years of post-doctoral training before subspecialty fellowship.

Mohs Surgery requires completion of an ACGME-accredited fellowship of at least 1 year, during which surgeons learn the technique of staged excision with immediate frozen-section or paraffin-section margin control. The American College of Mohs Surgery (ACMS) sets fellowship training standards. Mohs surgery achieves reported 5-year cure rates of up to 99% for primary basal cell carcinoma (ACMS, published outcome data), making margin control its defining clinical advantage over wide local excision. Detailed procedural information is available on the Mohs surgery explained page.

Pediatric Dermatology fellowships run 1–2 years and address conditions including epidermolysis bullosa, hemangiomas, genodermatoses, and atopic dermatitis in pediatric populations. The Society for Pediatric Dermatology (SPD) publishes training guidelines. Pediatric cases are distinct because drug dosing, skin barrier physiology, and disease presentation differ materially from adult norms — a consideration that affects prescribing under FDA pediatric labeling rules (FDA Pediatric Research Equity Act). More on pediatric dermatology conditions is available site-wide.

Dermatopathology is unique in that it carries dual-board eligibility through either the ABD or the American Board of Pathology (ABP), reflecting that both dermatologists and pathologists may pursue this subspecialty. Fellowship is typically 1 year.

Cosmetic Dermatology encompasses laser treatments, botulinum toxin injections, dermal fillers, and chemical peels. While not ABD-certified as a standalone subspecialty, the ASDS publishes practice guidelines and safety standards that function as the field's de facto credentialing benchmark. The FDA regulates injectable biologics and device-based treatments under separate premarket pathways (21 CFR Part 880 for devices; biologics licensing under 21 CFR Part 601).

Common Scenarios

Referral to a dermatology subspecialist typically follows one of four clinical patterns:

• High-risk skin cancer on the face, ears, or scalp — a general dermatologist identifies a basal cell or squamous cell carcinoma in a location where tissue conservation is critical, and refers to a Mohs surgeon.
• Pediatric atopic dermatitis refractory to standard care — a pediatrician or general dermatologist refers to a pediatric dermatologist when first- and second-line topical regimens fail or when systemic biologics such as dupilumab require specialist-level dosing oversight.
• Ambiguous biopsy finding — a dermatopathologist is consulted when routine histology returns an indeterminate result, particularly in cases involving melanocytic lesions where malignancy vs. benign diagnosis carries significant clinical consequences. Biopsy methodology is covered in the skin biopsy what to expect reference.
• Autoimmune bullous disease — conditions such as pemphigus vulgaris or bullous pemphigoid require immunofluorescence interpretation and systemic immunosuppression protocols that fall within immunodermatology scope.

Decision Boundaries

Subspecialty selection follows clinical decision logic grounded in diagnosis, anatomic site, patient age, and procedural complexity. The contrast below clarifies two commonly confused subspecialties:

Mohs Surgery vs. Standard Excision
Mohs is indicated when the tumor is located in high-risk anatomic zones (H-zone of the face), when margins are clinically ambiguous, when histologic subtype carries high recurrence risk (morpheaform BCC, for example), or when the patient is immunocompromised. Standard wide local excision with post-operative margin assessment is appropriate for low-risk tumors on the trunk or extremities where tissue conservation is not the primary concern. The skin cancer types and warning signs page outlines tumor classification relevant to these decisions.

Cosmetic vs. Medical Dermatology
The boundary between cosmetic and medical practice carries regulatory weight. Procedures coded as cosmetic are generally excluded from Medicare and Medicaid reimbursement under 42 CFR § 411.15(l), while procedures coded as medically necessary — including laser treatment for port-wine stains or phototherapy for psoriasis — may qualify for coverage. This distinction shapes how practices are structured, credentialed, and billed.

Pediatric vs. Adult-Focused Practice
The SPD identifies pediatric dermatology's functional scope as birth through 18 years, with neonatal dermatology representing a sub-niche within that range. Conditions like EB (epidermolysis bullosa) may warrant care extending into adulthood, requiring coordination between pediatric and adult-focused dermatologists at the 18-year transition boundary.

Board certification status is a key differentiator across all subspecialties. The board certification in dermatology page details the ABD examination structure and how subspecialty certificates are issued and maintained.

References

• American Board of Dermatology (ABD)
• Accreditation Council for Graduate Medical Education (ACGME) — Dermatology Program Requirements
• American College of Mohs Surgery (ACMS)
• American Society for Dermatologic Surgery (ASDS)
• Society for Pediatric Dermatology (SPD)
• FDA — Pediatric Research Equity Act Overview
• FDA — 21 CFR Part 601 (Biologics Licensing)
• CMS — 42 CFR § 411.15 (Excluded Services)

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)